Recently, we released an article highlighting that mesenchymal stem cell (MSC) scientific publications have increased in number for 26 years straight. Wow, that is a shockingly consistent trend.
Fascinatingly, two-thirds of those publications were released in the past 5 years, even though there is now a forty-year history of MSC publications.
What is equally fascinating is that the PubMed “Species” sort function indicates that 15,808 of all MSC scientific publications (28,597 to date) pertain to “Humans” rather than “Other Animals.”
Having 55.3% of MSC publications pertain to humans is an extremely promising finding for translating MSC research into therapeutic applications.
Whether you are manufacturing stem cell products, developing 3D printing applications, or offering cord blood and tissue storage services, you need to be aware of trends like this.
Explore our blog for more free content on mesenchymal stem cell (MSC) market trends or check out the global strategic report “Mesenchymal Stem Cells – Advances & Applications.”
*Note: PubMed search of terms “mesenchymal stem cell” and “mesenchymal stem cells” executed July 15, 2016.
BioInformant is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Medical Ethics, Vogue Magazine, and more. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs, BioInformant is your global leader in stem cell industry data.